Engineering a patient's own T cells to selectively target and eliminate tumour cells has cured
patients with untreatable haematologic cancers. These results have energized the field to …

Chimeric antigen receptor (CAR) T cell therapy represents a major breakthrough in cancer
care since the approval of tisagenlecleucel by the Food and Drug Administration in 2017 for …

Chimeric antigen receptor T (CART) cell immunotherapy has been remarkably successful in
treating certain relapsed/refractory hematological cancers. However, CART cell therapy is …

Adaptive immunity, orchestrated by B-cells and T-cells, plays a crucial role in protecting the
body from pathogenic invaders and can be used as tools to enhance the body's defense …

Chimeric antigen receptor (CAR) T cells have proven that engineered immune cells can
serve as a powerful new class of cancer therapeutics. Clinical experience has helped to …

The immune system evolved to distinguish non-self from self to protect the organism. As
cancer is derived from our own cells, immune responses to dysregulated cell growth present …

Highlights•CAR T cell clinical trial manufacturing data is investigated.•Three dominant
process routes are uncovered.•The trend in CAR T cell manufacturing is towards …

Adoptive T-cell therapy with gene-modified T cells expressing a tumor-reactive T-cell
receptor or chimeric antigen receptor (CAR) is a rapidly growing field of translational …

Chimeric antigen receptor (CAR) T cell therapies have evolved from a research tool to a
concept-shifting therapy with impressive responses in B cell malignancies. This Review …

One of the most exciting new therapies for cancer involves the use of autologous T cells that
are engineered to recognize and destroy cancerous cells. Patients with previously …